


Glenmark Pharmaceuticals Limited

PART I
Statement of Unaudited financial results for the quarter and Nine months ended 31 December 2013

Particulars [Refer notes below]		Standalone (Indian GAAP)						Consolidated (IFRS)					
		Quarter ended 31/12/2013 (Unaudited)	Quarter ended 30/09/2013 (Unaudited)	Quarter ended 31/12/2012 (Unaudited)	Nine months ended 31/12/2013 (Unaudited)	Nine months ended 31/12/2012 (Unaudited)	Year ended 31/03/2013 (Audited)	Quarter ended 31/12/2013 (Unaudited)	Quarter ended 30/09/2013 (Unaudited)	Quarter ended 31/12/2012 (Unaudited)	Nine months ended 31/12/2013 (Unaudited)	Nine months ended 31/12/2012 (Unaudited)	Year ended 31/03/2013 (Audited)
1. Income from Operations													
(a) Net Sales / Income from Operations (Net of excise duty)		5,303.18	5,830.26	5,348.91	16,213.22	14,511.52	19,352.88	16,012.23	14,630.06	13,812.59	43,021.11	36,768.57	50,123.42
(b) Other Operating Income		16.14	23.47	76.54	54.17	129.39	140.16	5.29	3.74	3.54	12.64	10.04	13.80
Total Income from Operations (net)		5,319.32	5,853.73	5,425.45	16,267.39	14,640.91	19,493.04	16,017.52	14,633.80	13,816.13	43,033.75	36,778.61	50,137.22
2. Expenses													
a. Cost of Materials consumed		1,047.28	1,025.76	1,067.01	3,292.53	3,123.80	4,157.50	3,427.04	4,027.28	4,381.71	11,051.15	11,076.44	12,782.23
b. Purchase of Stock-in-trade		398.73	338.39	467.74	1,120.22	1,064.90	1,410.88	1,362.10	1,167.62	1,101.46	3,325.80	2,907.26	3,922.20
c. Changes in Inventories of finished goods, work-in-progress and stock-in-trade		23.58	109.07	7.89	(68.47)	(57.10)	(36.67)	583.95	(326.32)	(806.01)	(85.40)	(1,217.68)	(168.41)
d. Employee benefits expense		1,053.01	1,142.63	793.10	2,926.79	2,288.12	3,030.17	2,734.66	2,644.70	2,123.74	7,487.55	5,794.99	7,882.38
e. Depreciation and Amortisation expense		80.47	70.51	63.06	217.70	186.14	250.41	611.01	605.24	356.39	1,564.99	952.03	1,270.09
f. Other expenses		2,034.04	2,114.38	1,993.11	5,795.95	5,478.16	7,606.72	4,260.03	3,963.71	3,813.61	11,970.28	10,651.47	15,605.14
Total expenses		4,637.11	4,800.74	4,391.91	13,284.72	12,084.02	16,419.01	12,978.79	12,082.23	10,970.90	35,314.37	30,164.51	41,293.63
3. Profit from Operations before Other Income, finance costs & exceptional items (1-2)		682.21	1,052.99	1,033.54	2,982.67	2,556.89	3,074.03	3,038.73	2,551.57	2,845.23	7,719.38	6,614.10	8,843.59
4. Other Income		112.34	206.53	133.96	540.43	896.65	1,162.45	50.80	134.04	51.51	218.20	143.26	93.67
5. Profit from ordinary activities before finance costs and exceptional items (3+4)		794.55	1,259.52	1,167.50	3,523.10	3,453.54	4,236.48	3,089.53	2,685.61	2,896.74	7,937.58	6,757.36	8,937.26
6. Finance costs		83.59	60.53	113.13	237.39	373.62	436.94	472.71	484.57	399.92	1,421.68	1,164.21	1,600.11
7. Profit from ordinary activities after finance costs but before Exceptional Items (5-6)		710.96	1,198.99	1,054.37	3,285.71	3,079.92	3,799.54	2,616.82	2,201.04	2,496.82	6,515.90	5,593.15	7,337.15
8. Exceptional items		-	-	-	-	-	-	-	-	-	-	-	-
9. Profit from Ordinary Activities before tax (7-8)		710.96	1,198.99	1,054.37	3,285.71	3,079.92	3,799.54	2,616.82	2,201.04	2,496.82	6,515.90	5,593.15	7,337.15
10. Tax Expense		126.87	139.51	(35.99)	464.15	68.04	(61.53)	473.51	628.01	366.34	1,494.01	1,061.50	1,107.15
11. Net Profit from Ordinary Activities after tax (9-10)		584.09	1,059.48	1,090.36	2,821.56	3,011.88	3,861.07	2,143.31	1,573.03	2,130.48	5,021.89	4,531.65	6,230.00
12. Extraordinary items		-	-	-	-	-	-	-	-	-	-	-	-
13. Net Profit for the period (11-12)		584.09	1,059.48	1,090.36	2,821.56	3,011.88	3,861.07	2,143.31	1,573.03	2,130.48	5,021.89	4,531.65	6,230.00
14. Share of profit/(loss) of associates		-	-	-	-	-	-	-	-	-	-	-	-
15. Minority Interest		-	-	-	-	-	-	(19.05)	30.06	1.31	29.80	52.21	82.57
16. Net Profit after taxes, minority interest and share of profit/(loss) of associates (13-14-15)		584.09	1,059.48	1,090.36	2,821.56	3,011.88	3,861.07	2,162.36	1,542.97	2,129.17	4,992.09	4,479.44	6,147.43
17. Paid-up Equity Share Capital (Face value per share Re. 1)		271.12	271.01	270.74	271.12	270.74	270.85	271.12	271.01	270.74	271.12	270.74	270.85
18. Reserves excluding Revaluation reserves as per Balance sheet of previous accounting year		-	-	-	-	-	24,960.93	-	-	-	-	-	27,359.40
19.i Earning Per Share (before extraordinary items) (of Re 1/- each) (not annualised) Basic Earnings Per Share (in Rs.) Diluted Earnings Per Share (in Rs.)		2.15 2.15	3.91 3.91	4.03 4.02	10.41 10.40	11.13 11.12	14.26 14.25	7.98 7.97	5.69 5.69	7.86 7.86	18.42 18.41	16.55 16.53	22.71 22.69
19.ii Earning Per Share (after extraordinary items) (of Re 1/- each) (not annualised) Basic Earnings Per Share (in Rs.) Diluted Earnings Per Share (in Rs.)		2.15 2.15	3.91 3.91	4.03 4.02	10.41 10.40	11.13 11.12	14.26 14.25	7.98 7.97	5.69 5.69	7.86 7.86	18.42 18.41	16.55 16.53	22.71 22.69

PART II
Select information for the quarter and Nine months ended 31 December 2013

Particulars	Quarter ended 31/12/2013	Quarter ended 30/09/2013	Quarter ended 31/12/2012	Nine months ended 31/12/2013	Nine months ended 31/12/2012	Year ended 31/03/2013	Quarter ended 31/12/2013	Quarter ended 30/09/2013	Quarter ended 31/12/2012	Nine months ended 31/12/2013	Nine months ended 31/12/2012	Year ended 31/03/2013
A Particulars of Shareholding												
1. Public Shareholding												
Number of Shares	140,169,336	140,079,736	139,907,854	140,169,336	139,907,854	140,014,454	140,169,336	140,079,736	139,907,854	140,169,336	139,907,854	140,014,454
Percentage of Shareholding	51.70	51.69	51.68	51.70	51.68	51.69	51.70	51.69	51.68	51.70	51.68	51.69
2. Promoters and promoter group Shareholding												
a) Pledged/Encumbered												
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered												
- Number of Shares	130,955,617	130,925,617	130,830,199	130,955,617	130,830,199	130,839,199	130,955,617	130,925,617	130,830,199	130,955,617	130,830,199	130,839,199
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	48.30	48.31	48.32	48.30	48.32	48.31	48.30	48.31	48.32	48.30	48.32	48.31



Glenmark Pharmaceuticals Ltd.

Glenmark House, HDO-Corporate Building, Wing A, B D Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai 400 099
T : 91 22 4018 9999 F : 91 22 4018 9986 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026.



	Particulars	Quarter ended 31/12/2013
B	Investors complaints	
	Pending at the beginning of the quarter	-
	Received during the quarter	12
	Disposed off during the quarter	12
	Remaining unresolved at the end of the quarter	-

Notes:

- 1 The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors held on January 24, 2014.
- 2 The Company is exclusively in the Pharmaceutical business segment.
- 3 During the quarter ended December 31, 2013, pursuant to Employee Stock Option Scheme 2003, the Company converted 119,600 options into equity shares of Re.1 each. As at December 31, 2013, 482,500 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 4 Tax expenses is computed after considering MAT credit and other income tax benefits.
- 5 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 6 The Standalone Financial Statements have been prepared in accordance with accounting principles generally accepted in India including the Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended).
- 7 The Company has voluntarily adopted IFRS (International Financial Reporting Standards) in preparation of the consolidated financial statements as per the requirements of SEBI circular dated April 5, 2010, accordingly the consolidated results have been prepared in accordance with the recognition and measurement principles as per IFRS and presented in the format as per clause 41 of the listing agreement.
- 8 Previous period's figures have been re-grouped/re-classified wherever necessary.

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director

Mumbai, 24 January, 2014